UK-CAB 18 – HIV related dementia

1 September 2006

Programme for the meeting
Reading material
Post meeting report
Post meeting report Word document [80 Kb]

PowerPoint Slides from the meeting
Feedback from Toronto [1.92 MB]
Background to dementia [656 kb]

Programme

09:30 – 10.00 Registration and coffee
10.00-11.30 Feedbacki) World Haempophilia conference in Vancouver

ii) EATG

iii) Transmission conferences in London and Keele

iv)  Email discussions on mandatory testing

v)  BHIVA treatment guidelines

vi) BHIVA standards of care meeting

vii) Elections to new steering group

viii)  Future UK-CAB meetings and subjects for training

11:30 – 12:30 Feedback from Toronto – Simon Collins
12:30 – 13.30 Lunch
13:30 – 14:15 Assessment for HIV brain impairment / Related Dementia – Heather George, Psychologist
14.15 – 15:30 Break
14.30 – 15:30 Background to dementia, damage to the brain, HIV related encephalopathy and treatments – Jeanette Meadway, Physician
15:30 – 16.00 Discussion on Dementia available service provision, funding for care, etc.

Reading material

HIV dementia

http://www.emedicine.com/neuro/topic447.htm

This site offers a background into neurological complications from HIV, provides simple information about how it occurs, the frequency, diagnosis and treatment. There are also a range of links to other related topics.

Update on the Neurological Manifestations of HIV

Justin McArthur, MBBS, MPH

PDF File [192 Kb]

AIDS Dementia Complex

Dementia is a brain disorder that affects a person’s ability to think clearly and can impact his or her daily activities. AIDS dementia complex (ADC)-dementia caused by HIV infection-is a complicated syndrome made up of different nervous system and mental symptoms. These symptoms are somewhat common in people with HIV disease.

Project Inform factsheet, April 2002

http://www.projinf.org/fs/dementia.html

Financial support

The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.

The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.

We believe that manufacturers who currently develop and market medicines have a responsibility to actively engage with advocacy organisations and that HIV positive people and their advocates should be able to directly question manufacturers about the safety and efficacy of their products and proposals for future research.

For a list of companies that support the UK-CAB please see the “about us” page.

Link to top of page

Edit
Published: September 1, 2006
Last edited: August 14, 2013